S&T News-Innovation

From consulting and strategy development to implementation and support, our comprehensive services can help your business thrive.

The Nobel PrizeThe Nobel Prize827,507 followers827,507 followers19h • 19 hours ago

Follow

BREAKING NEWS
The Nobel Assembly at the Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

This year’s Nobel Prize honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated.

The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type.

This year’s medicine laureates Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.

A gathering of the brightest minds in stem cell research across geographies and disciplines.

The world's best and brightest in stem cell research and regenerative medicine convene once a year for the ISSCR Annual Meeting, and you are invited! Join more than 4,000 scientists from around the globe at ISSCR 2024 to take part in a 4-day program comprising the year's most significant new advances in the field.

Out-of-this-world techniques: microgravity leads to tissue engineering breakthroughs

21 Oct 2024

Written by Beatrice Bowlby (Digital Editor)

Out-of-this-world techniques: microgravity leads to tissue engineering breakthroughs

Microgravity offers a unique condition for tissue engineering, advancing stem cell-derived liver tissue development. But how can we transport these tissues to Earth without damaging them?

Read this story | 3 mins

New PODCAST
Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field
Eric Faulkner

Cell & Gene Therapy Insights 2024; 10(7), 1043–1053

If you enjoyed this episode, you can listen to all episodes from The BioInsights Podcast wherever you normally get your podcasts.

Having worked in advanced therapies for nearly three decades and across hundreds of strategic asset scenarios, what do you see as the greatest challenges in the industry then versus now?

EF: The first approved gene therapies faced much the same challenges as the first cell therapy products that preceded them. These early advanced therapies were introduced into reimbursement systems that were never designed for transformative, single-administration therapies. Every aspect of therapy development, supply chain, evidence development, reimbursement, and provider-side dynamics had to be considered. Many of these challenges still exist, similarly to the dynamics of drug-diagnostic combinations in precision medicine.
Read more

New PODCAST
RxCell Inc. Granted U.S. Patent for iPSC-based Cell Therapy

By Cade Hildreth (CEO) on September 27, 2024

PARK CITY, Utah, September 19, 2024 - RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled "Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source", a significant advancement in the field of regenerative medicine. This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases.

• Retinal Cells: Targeting retinal degenerative diseases such as age-related macular degeneration.

• Dopaminergic Neurons: Addressing neurodegenerative disorders like Parkinson’s disease.

• Neural Lineages: Generating various neural cell types for treating neurological conditions.

• Hepatocytes: Developing liver cell therapies for hepatic diseases.

• Endothelial and Mesenchymal Cells: Producing vascular and connective tissue cells for a range of therapeutic applications.

3D-printing vascular grafts to mimic human blood vessels

1 Aug 2024

3D-printing vascular grafts to mimic human blood vessels

.Researchers at the University of Edinburgh (UK) present a novel two-stage tissue engineering process to create better vascular grafts for use in bypass surgeries.

Many cardiovascular diseases ultimately require bypass surgery, whereby a vascular graft is installed to navigate blood flow around a damaged blood vessel. Currently, autologous grafts are the mainstay of treatment, which generally involves the removal of vessels from the leg, arm or chest to replace faulty cardiac arteries. However, these often confer issues at the donor site and do not possess the mechanical properties required to adequately replace native vessels. Synthetic grafts have limited use in larger-diameter arteries, but for smaller vessels they frequently result in infection or intimal hyperplasia – where thickness is reduced by cell growth inside the lumen.

New

New

Creative Medical Technology Announces iPSCelz® Program Has Generated iPSC Derived Islet Cells that Produce Human Insulin

BioInformantRead on blog or Reade

By Cade Hildreth (CEO) on July 23, 2024

PHOENIX, June 24, 2024 -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin.

The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company’s iPSCelz® program, which is validated by Greenstone Biosciences Inc. (“Greenstone”). The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated

To learn more about the expanding market for iPSCs, view the “Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report - Market Size, Trends, and Forecasts.”

New data presented at CAR-TCR Europe demonstrates that it’s now possible to rapidly expand CAR T cells to clinically relevant doses, even when autologous starting material is scarce. That has the potential for a meaningful impact on patients who may have difficulty producing enough starting cells.

In a study, the expansion of 15 million CAR T cells to 2.6 billion within 7 days demonstrated, for the first time, the ability to rapidly produce high-quality CAR T cells, using protocols developed by Terumo Blood and Cell Technologies for the Quantum Flex™ Cell Expansion System and the Finia™ Fill and Finish System. BioCentriq, a CDMO, generated the data on the two platforms, in tandem with its own LEAP Advanced Therapy Platform.

Watch on demand as David Smith, PhD, Vice President of Development at BioCentriq, shares the data and his analysis. You’ll also hear what he’s learned about the importance of technology transfer, as well as keeping the end in sight, beginning with process development.

https://share.vidyard.com/watch/SpefpbRxAkMTbH4D88QdjT?

Watch video

Rapid, high-quality cell expansion